BioSpace News Archive

Basilea Pharmaceutica Ltd. announced that updated interim results from cohort 2 of the phase 2 study FIDES-01 were presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium 2022, held from January 20 to 22, in San Francisco, USA.

MaaT Pharma announced positive interim engraftment data from the first four cohorts of the CIMON trial with MaaT033, the Company’s high-richness, high-diversity, Microbiome Ecosystem Therapy for oral administration.

Verona Pharma plc announces it has completed patient enrollment with more than 800 subjects randomized in the ENHANCE-2 trial, evaluating ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease.

BeiGene announced positive findings from the global Phase 3 RATIONALE 305 trial of tislelizumab versus placebo in combination with chemotherapy as a first-line treatment for patients with locally advanced, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

Magnesium Development Company (MDC) has received the FDA’s Breakthrough Device designation, having exceeded the criteria required for participation in the Breakthrough Device Program.

Immuneering Corporation announced that Ben Zeskind, Ph.D., Co-Founder, President and Chief Executive Officer of Immuneering, Biren Amin, MBA, Chief Financial Officer and Brett Hall, Ph.D., Chief Scientific Officer, will participate in upcoming investor conferences to share commentary with investors around the Company’s pipeline, platform and business strategy.

CytoSorbents Corporation highlights a new publication in the peer-reviewed journal, Annals of Thoracic and Cardiovascular Surgery , entitled " Hemoadsorption of Rivaroxaban and Ticagrelor during Acute Type A Aortic Dissection Operations.”

NeoGenomics, Inc. announced a strategic partnership with the Biomarker Collaborative to help cancer patients who test positive for specific biomarkers connect to support groups that include patients with similar findings.

NeoImmuneTech, Inc. today announced the publication of preclinical data evaluating the company’s lead asset NT-I7 (efineptakin alfa), a novel T cell amplifier, in mouse models of glioblastoma (GBM).

EdiGene, Inc. announced a research and development collaboration with Haihe Laboratory of Cell Ecosystem to develop hematopoietic stem cell regenerative therapies and platform technology by combining resources and expertise from both sides.